Emergent BioSolutions (EBS) Misses Q4 EPS by 81c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.01 --0%
Revenue Growth %: +32.0%
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
CRMT, PXED, AEHR, More
Revenue Growth %: +32.0%
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
CRMT, PXED, AEHR, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of ($0.43), $0.81 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $148.7 million versus the consensus estimate of $237 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KeyBanc Highlights Murphy Oil Corp. (MUR) Into Earnings
- AstraZeneca licenses sunvozertinib from Dizal for $600M upfront
- WISeKey reports 115% revenue rise in H1 2026, reaffirms FY outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
